POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the US Food and Drug Administration approval of VIMOVOâ``¢ delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.
POZEN announces receipt of $20 million milestone payment from AstraZeneca